ST
PGNX

Spot Trading’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Spot Trading’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,400
Closed -$6K – 3999
2016
Q1 		$6K Buy
+1,400
New +$6.24K ﹤0.01% 3222

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spot Trading's PGNX Position: Q2 2016 in Review

Spot Trading sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2016, closing a stake of 1,400 shares — an estimated $6K sold.

Spot Trading first reported a position in PGNX in Q1 2016 and held it in 1 quarter. The position peaked at $6K in Q1 2016. 104 funds tracked by Wall St. Rank hold PGNX as of Q2 2016.

  • Spot Trading reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Spot Trading sold 1,400 Progenics Pharmaceuticals Inc shares in Q2 2016, an estimated $6K.
  • Spot Trading first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 1 quarter.
  • Spot Trading's Progenics Pharmaceuticals Inc position peaked at $6K in Q1 2016.
  • 104 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2016.

Based on Spot Trading's 13F filing for Q2 2016, filed 2 Aug 2016.